Replies to post #778390 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

I specifically said updates about regulatory filings which they are planning , not the one under review.

Though they are allowed to discuss reviews in progress, it is true many companies elect not to. So I would not red flag NWBO on that either, And I agree with you there is plenty they can discuss with a Q2 conference call in a couple weeks.

1) What is the plan for regulatory submissions in the US/EU?
2) What are the actual trials licensed from Roswell Park?
3) Why is Specials revenue so small compared to asserted patient numbers?
4) Is there a contract in place with Advent for commercial manufacturing?
5) What is the status of the trial INDs for Direct and a -L combo?
6) What is a schedule for the Grade C cleanroom construction?
7) What is a schedule for Eden comparability testing?
8) What is the best way to prepare crab-cakes?

All of these are things most all dev stage bios would discuss to some extent, even if saying on some items the will not yet provide an update.